Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000242631 | SCV000320277 | pathogenic | Cardiovascular phenotype | 2015-09-29 | criteria provided, single submitter | clinical testing | The c.295dupC pathogenic mutation, located in coding exon 2 of the GLA gene, results from a duplication of C at nucleotide position 295, causing a translational frameshift with a predicted alternate stop codon (p.Q99Pfs*24). Since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Eurofins Ntd Llc |
RCV000384832 | SCV000339554 | pathogenic | not provided | 2016-02-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001807204 | SCV002054447 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |